ALVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Alvotech SA (ALVO) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock faces significant challenges, including regulatory setbacks, ongoing legal investigations, and weak financial performance. While there is some potential for recovery in the long term, the lack of positive trading signals, bearish technical indicators, and mixed analyst sentiment suggest that holding off on investment is prudent for now.
The technical indicators for ALVO are bearish. The MACD histogram is negative and contracting, indicating weak momentum. The RSI is neutral at 26.47, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 4.018, with resistance at 4.786. Overall, the trend does not indicate a favorable entry point.
Revenue increased by 10.56% YoY in Q3 2025, and gross margin improved by 12.91% YoY to 69.26%. Analyst sentiment from Morgan Stanley maintains an Overweight rating with a reduced price target of $10, suggesting potential long-term value.
The company received a Complete Response Letter from the FDA due to compliance issues, leading to a significant stock drop of 34.25%. There is an ongoing investigation into potential securities law violations. Net income dropped by 53.90% YoY, and EPS declined by 50.00% YoY. Technical indicators are bearish, and there are no significant insider or hedge fund trading trends.
In Q3 2025, Alvotech's revenue increased by 10.56% YoY to $113.86M, but net income dropped by 53.90% YoY to -$5.25M. EPS declined by 50.00% YoY to -$0.02. Gross margin improved to 69.26%, up 12.91% YoY. Despite revenue growth, the company's profitability metrics are deteriorating.
Barclays initiated coverage with an Underweight rating and a $5 price target, citing a transitional phase in the specialty pharmaceuticals industry. Morgan Stanley lowered its price target from $14 to $10 but maintained an Overweight rating, highlighting neutral sentiment in the EU Pharmaceuticals sector with better EPS growth elsewhere in Europe.
